Business Wire

JAMPRO

30.8.2021 17:02:10 CEST | Business Wire | Press release

Share
Jamaica’s Manufacturing Sector to Play Strong Role in Economic Recovery

Jamaica’s manufacturing sector has shown resilience through the COVID-19 pandemic, with the country seeing positive developments in industries such as chemicals and cosmetics.

Manufacturers have seized new opportunities to export to markets that have experienced disruptions in their supply chains. This has led to increased production of items like cleaning chemicals, sanitizers, masks, and OTC pharmaceuticals to meet local and international demand. Jamaica expects this manufacturing expansion to contribute significantly to its economic recovery effort in the next 5 years.

These developments support the island’s goal to be a manufacturing leader in the region. Its government has long highlighted the sector as an area for growth as a myriad of possibilities exist, and Jamaica is strategically located to easily access key markets like the United States, the United Kingdom, Canada, CARICOM and Latin America.

Jamaica has one of the most diverse manufacturing sectors in the Caribbean, ranging from large food-based manufacturing giants such as GraceKennedy Limited and Jamaica Producers Group , to a burgeoning “clean beauty” industry with companies like Ettenio and Irie Rock manufacturing hair and skin care for local and international consumers.

The manufacturing of medical devices, electronics, building materials, and product fitting and assembly are other activities taking place on the island. Contract manufacturing is also an emerging area, as companies seek to use the island as their manufacturing and export base. Jamaica benefits from preferential market access to several regions through trade agreements, further strengthening its position as an ideal contract manufacturing location.

Building on this strong manufacturing tradition, Jamaica’s trade and investment promotions agency, JAMPRO , says that the stage is set for more industries to grow, even with constraints created by the pandemic.

President of JAMPRO, Diane Edwards, explained, “Jamaicans are resourceful, innovative, and committed, and because of that our manufacturing sector continues to find new ways to develop products that are in demand. There are difficulties, but there are opportunities, so the government has been working to give this sector the support it needs to thrive during the pandemic.”

At JAMPRO, this assistance has included engaging manufacturers and investors to produce more value-added goods. The organisation has ongoing initiatives that deliver business-matchmaking services, and facilitates the packaging and promotion of investment projects.

In collaboration with the Jamaica Manufacturers and Exporters Association Limited (JMEA), JAMPRO also provides education and awareness around important subjects like incentives, the Special Economic Zone (SEZ) framework, and regional and global trade agreements that are favourable for products manufactured in Jamaica. The aim is to enhance opportunities for persons to do business in the island.

Positive outlook for manufacturing

With recent global trends in nearshore manufacturing and increased consumption of goods, JAMPRO envisages that more manufacturing will be taking place in Jamaica.

Global health and lifestyle trends will fuel the production of high value goods such as Jamaican Black Castor Oil and its derivatives, and cosmetics made with natural ingredients. According to Transparency Market Research (TMR) the global cosmetics ingredients market, valued at US$30 Bn in 2020, is expected to attain a market value of US$51.6 Bn by 2030.

TMR also notes the rising popularity of natural/herbal cosmetics products, as these items are viewed as healthier alternatives. This creates an excellent opportunity for Jamaica, which currently grows several of the ingredients needed to manufacture these goods.

Reflecting on these trends, Berletta Henlon Forrester, Manager of Manufacturing and Mining at JAMPRO, stated, “Entrepreneurs can explore manufacturing beyond food and beverage, and diversify into health & beauty, packaging & paper, and household chemicals. These industries are supported by Jamaica’s capacity to provide an abundance of ingredients such as bamboo, castor, turmeric, aloe vera and cannabis, to name a few .”

To produce the ideal ecosystem for the success of the aforementioned industries, Jamaica is embarking on a National Five-Year Manufacturing Growth Strategy and is executing government reforms to improve the ease of doing business. This combination should foster the growth of manufacturing and strengthen the sector’s overall performance.

Forrester said, “This is the right time for ambitious manufacturers and investors, both large and small, to initiate their strategies towards Jamaica as the location for their manufacturing project . JAMPRO will be available, as always, to provide the necessary guidance and assistance.”

ABOUT JAMPRO

The Jamaica Promotions Corporation (JAMPRO)’s mission is to drive economic development through growth in investment and export. JAMPRO is an Agency of the Ministry of Industry, Investment, and Commerce.

For more information on JAMPRO, please visit https://dobusinessjamaica.com/ .

Follow us on:
Twitter
Facebook
Instagram
LinkedIn

Link:

ClickThru

Social Media:

https://www.facebook.com/jamprocorp

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release

New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu

Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release

Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope

Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release

Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co

SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release

The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release

Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye